“The data from this large Phase 2 study show a remarkable improvement in overall survival in a well-defined patient population. This suggests that Sym004 could be a unique precision medicine opportunity for patients with late-stage metastatic colorectal cancer that otherwise have very limited or no treatment options” said Martin Olin, Chief Executive Officer of Symphogen.
Oral Presentation:
Title: 478O – Efficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S)
Session Date: Monday 11 September, 09:30 – 09:45
Authors: J. Tabernero, F. Ciardiello, C. Montagut, C. Ding, S. Kopetz, T. Tuxen Poulsen,
A. Bardelli, L. Wyrwicz, A. Cubillo, C. Santos, G. Fumi, V. Zagonel, J. Bennouna,
S. Siena, A. Falcone, M. Benavent, G. Argiles, M. Kragh, I. Horak, M. Dvorkin
Presenter: J. Tabernero
In addition, Symphogen will present the following poster at the congress:
Title: 123P – Genotyping circulating tumor DNA identifies metastatic colorectal cancer (mCRC) patients highly sensitive to Sym004
Session Date: Monday 11 September, 13:15-14:15
Authors: C. Montagut, A. Bardelli, T. Tuxen Poulsen, R. Dienstmann, M. Kragh, S. Kopetz,
K. Koefoed, F. Ciardiello, C. Ding, J. Vidal, J. Clausell-Tormos, G. Siravegna,
T. Lindsted, M.W. Pedersen, G. Rospo, G. Argilés Martinez, P. Nadler, I. Horak,
J. Tabernero
Presenter: C. Montagut
Full session details and data presentation listings for ESMO 2017 Congress can be found at http://www.esmo.org/Conferences/ESMO-2017-Congress/Programme
About Sym004
Sym004 is comprised of two antibodies targeting non-overlapping epitopes on EGFR that are designed to not only block ligand induced receptor activation but also to elicit removal of EGFR from the cancer cell surface by inducing receptor internalization and degradation. Positive clinical efficacy findings for Sym004 in patients with metastatic colorectal cancer (mCRC) and with acquired resistance to anti-EGFR antibody was reported in the June 2015 issue of Cancer Discovery (Cancer
Discov. 2015 Jun;5(6):598-609).
For additional information, please contact:
Martin Olin, Chief Executive Officer
Phone: +45 40 21 85 32
E-mail: mol@symphogen.com
International media
Consilium Strategic Communications
Phone: +44 20 3709 5700
E-mail: symphogen@consilium-comms.com